ArticleEBioMedicine2022

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.

Milana A Bergamino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.